• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2020.15124

Tumor angiogenesis and lymphoangiogenesis at the application of neoadjuvant chemotherapy with bevacizumab depending on g rowth patterns of cervical cancer

[Oncology]
Nelly Albertovna Nazaralieva; Alexey Maksimov; Ekaterina Komarova; Victoria Pozdniyakova; Elizaveta Yuryevna Komarova;

In 74 patients with cervical cancer (T1b2-T2bNxM0) treated with neoadjuvate chemotherapy (n=25), including with bevacizumab (n=49), the level of vasculoendothelial growth factors (VEGF-A, VEGF-D) and their receptors (VEGF-R2, VEGF-R3) in surgical biopsies was studied by ELISA. In the tumor, peritumoral and visually intact tissues of endophytic formations treated with bevacizumab, there was a pronounced decrease in the VEGF-A/VEGF-R2 ratio (by 4, 10 and 22 times, respectively) due to an increase in VEGF-R2 levels (by 2.0; 8.8 and 13.2 times, respectively) and a decrease in VEGF-A values (1.8 times in tumor and 1.5 times in visually intact tissues). In exophytic cervical cancer, the decrease in the VEGF-A/VEGF-R2 ratio during bevacizumab therapy was less pronounced (by 3.0; 3.3 and 8.3 times, respectively) and was associated with an increase in the VEGF-R2 content (by 2.5; 2.2 and 8.1 times in tumor, peritumoral and visually intact tissues, respectively). VEGF-D values were decreased in all cervical cancer tissues, especially in endophytic tumors. Thus, the use of bevacizumab in locally advanced cervical cancer together with neoadjuvate chemotherapy inhibits the expression of angiogenic growth factors and activates the inhibitory system of neoangiogenesis, inhibits the processes of lymphoangiogenesis.

Download

References:
1. Chekhonin V. P., Shein S. A., Korchagina A. A., Gurina O.I . VEGF inneoplasticangiogenesis. Vestnik RAMN. – Bulletin of the RAMS. 2012;2:23-34. (In Russ.). https://doi.org/10.15690/vramn.v67i2.119
2. Kit O. I., Franciyanc E. M., Nikipelova E. A., Komarova E. F. Some indices of neoplastic angiogenesis in tissue of rectal tumors with various morphological structures. Rossijskij onkologicheskij zhurnal. – Russian Journal of Oncology. 2015;20(2):12-18. (In Russ.).
3. Kononenko V. I., Kit O. I., Komarova E. F., Maksimov A. Yu., Pozdnyakova V. V. [et al.]. Evaluation of the expression of transcription, neoangiogenesis and apoptosis factors in case of postoperative complications in patients with different progression of oral mucosa cancer. Kubanskij nauchnyj medicinskij vestnik. – Kuban Scientific Medical Bulletin. 2017;1(162):64-68. (In Russ.). https://doi.org/10.25207/1608-6228-2017-1-64-68
4. Zhang J., Liu J., Zhu C., He J., Chen J. [et al.]. Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis. Oncotarget. 2017;8(15):2479-7803. https://doi:10.18632/oncotarget.15044
5. Ferrara N., Adamis A. P. Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews. Drug Discovery. 2016;15(6):385-403. https://doi:10.1038/nrd.2015.17
6. Jayson G. C., Kerbel R., Ellis L. M., Harris A. L. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518-529. https://doi:10.1016/S0140-6736(15)01088-0
7. Tewari K. S., Sill M. W., Long H. J., Penson R. T., Huang H. [et al.]. Improved survival with bevacizumab in advanced cervical cancer. New England J. Med. 2014;370:734-743. https://doi:10.1056/NEJMoa1309748
8. Tewari K. S., Sill M. W., Penson R. T., Huang H., Ramondetta L. M. [et al.]. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654-1663. https://doi:10.1016/S0140-6736(17)31607-0
9. Kalabanova E. A., Nerodo G. A., Gus’kova E. A., Rozenko L. Ya. K voprosu o metastazirovanii i recidivirovanii pri rake shejki matki. Sibirskij onkologicheskij zhurnal. – Siberian Journal of Oncology. 2009;1:87-88. Available at: https://elibrary.ru/item.asp?id=12903382. Accessed June 28, 2019. (In Russ.).
10. Petrova V., Annicchiarico-Petruzzelli M., Melino G., Amelio I. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10. https://doi:10.1038/s41389-017-0011-9
11. Fil’chenkov A. A. Lymphangiogenesis and tumor metastasis. Onkologiya. – Oncology. 2009;11(2):93-102. (In Russ.).
12. Ma D. M., Xu Y. P., Zhu L. Expression of vascular endothelial growth factor C correlates with a poor prognosis based on analysis of prognostic factors in patients with cervical carcinomas. J. Obstetrics Gynaecol. Res. 2011;37(11):1519-1524. https://doi:10.1111/j.1447-0756.2011.01566.x
13. Secker G. A., Harvey N. L. VEGFR signaling during lymphatic vascular development: from progenitor cells to functional vessels. Development Dynamics. 2015;244(3):323-331. https://doi:10.1002/dvdy.24227

Keywords: vascular endothelial growth factor, angio- and lymphoangiogenesis, locally advanced cervical cancer, neoadjuvant therapy, bevacizumab